CA2335913C - Utilisation de solutions salines isoosmotiques, leur procede de preparation et medicaments cerumenolytiques a base de ces solutions - Google Patents
Utilisation de solutions salines isoosmotiques, leur procede de preparation et medicaments cerumenolytiques a base de ces solutions Download PDFInfo
- Publication number
- CA2335913C CA2335913C CA2335913A CA2335913A CA2335913C CA 2335913 C CA2335913 C CA 2335913C CA 2335913 A CA2335913 A CA 2335913A CA 2335913 A CA2335913 A CA 2335913A CA 2335913 C CA2335913 C CA 2335913C
- Authority
- CA
- Canada
- Prior art keywords
- solution
- cerumenolytic
- solutions
- isoosmotic
- iso
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 title claims abstract description 22
- 239000002415 cerumenolytic agent Substances 0.000 title claims abstract description 19
- 239000003814 drug Substances 0.000 title claims abstract description 14
- 239000011780 sodium chloride Substances 0.000 title abstract description 5
- 229940079593 drug Drugs 0.000 title description 9
- 238000000034 method Methods 0.000 title description 3
- 239000013535 sea water Substances 0.000 claims abstract description 6
- 239000000126 substance Substances 0.000 claims description 4
- 239000000243 solution Substances 0.000 description 38
- 210000002939 cerumen Anatomy 0.000 description 14
- 238000000326 densiometry Methods 0.000 description 9
- 238000002360 preparation method Methods 0.000 description 8
- 206010050337 Cerumen impaction Diseases 0.000 description 6
- 235000002639 sodium chloride Nutrition 0.000 description 6
- 229940126601 medicinal product Drugs 0.000 description 5
- 230000000694 effects Effects 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 239000011575 calcium Substances 0.000 description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical class OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- KWIUHFFTVRNATP-UHFFFAOYSA-N glycine betaine Chemical compound C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 2
- 230000002101 lytic effect Effects 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 2
- 239000012266 salt solution Substances 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- RMTFNDVZYPHUEF-XZBKPIIZSA-N 3-O-methyl-D-glucose Chemical compound O=C[C@H](O)[C@@H](OC)[C@H](O)[C@H](O)CO RMTFNDVZYPHUEF-XZBKPIIZSA-N 0.000 description 1
- 239000005635 Caprylic acid (CAS 124-07-2) Substances 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 229910000831 Steel Inorganic materials 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 229960003237 betaine Drugs 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000004320 controlled atmosphere Methods 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 210000000613 ear canal Anatomy 0.000 description 1
- 210000000959 ear middle Anatomy 0.000 description 1
- 238000000909 electrodialysis Methods 0.000 description 1
- 230000008588 hemolysis Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- WWZKQHOCKIZLMA-UHFFFAOYSA-M octanoate Chemical compound CCCCCCCC([O-])=O WWZKQHOCKIZLMA-UHFFFAOYSA-M 0.000 description 1
- 229960002446 octanoic acid Drugs 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000001732 sebaceous gland Anatomy 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000004290 sodium methyl p-hydroxybenzoate Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 239000010959 steel Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/02—Medicinal preparations containing materials or reaction products thereof with undetermined constitution from inanimate materials
- A61K35/08—Mineral waters; Sea water
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Steroid Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR98/08249 | 1998-06-29 | ||
| FR9808249A FR2780284B1 (fr) | 1998-06-29 | 1998-06-29 | Utilisation de solutions salines isoosmotiques, leur procede de preparation et medicaments cerumenolytiques a base de ces solutions |
| PCT/FR1999/001564 WO2000000208A1 (fr) | 1998-06-29 | 1999-06-29 | Utilisation de solutions salines isoosmotiques, leur procede de preparation et medicaments cerumenolytiques a base de ces solutions |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2335913A1 CA2335913A1 (fr) | 2000-01-06 |
| CA2335913C true CA2335913C (fr) | 2010-10-19 |
Family
ID=9528002
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2335913A Expired - Fee Related CA2335913C (fr) | 1998-06-29 | 1999-06-29 | Utilisation de solutions salines isoosmotiques, leur procede de preparation et medicaments cerumenolytiques a base de ces solutions |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US6709680B1 (enExample) |
| EP (1) | EP1091746B1 (enExample) |
| JP (1) | JP2002519330A (enExample) |
| AT (1) | ATE212553T1 (enExample) |
| AU (1) | AU4376599A (enExample) |
| CA (1) | CA2335913C (enExample) |
| DE (1) | DE69900852T2 (enExample) |
| DK (1) | DK1091746T3 (enExample) |
| ES (1) | ES2172332T3 (enExample) |
| FR (1) | FR2780284B1 (enExample) |
| PT (1) | PT1091746E (enExample) |
| WO (1) | WO2000000208A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2803205B1 (fr) * | 1999-12-31 | 2002-10-18 | Goemar Lab Sa | Solutions ioniques aqueuses et leurs utilisations notamment en ophtalmologie |
| KR100785441B1 (ko) | 2006-07-13 | 2007-12-13 | 주식회사 워터비스 | 해양 심층수 미네랄을 함유하는 항균성 생리식염수 |
| FR2915389B1 (fr) * | 2007-04-26 | 2012-12-21 | De La Mer Laboratoire | Utilisation de solutions ioniques isoosmotiques a base d'eau de mer pour la fabrication de dispositifs medicaux pour la prevention des complications du rhume courant |
| US20090258091A1 (en) * | 2008-04-09 | 2009-10-15 | Marine Bio Co., Ltd. | Compositions and methods for treating neurodegenerative diseases |
| AU2009253696A1 (en) | 2008-05-30 | 2009-12-03 | The University Of British Columbia | Methods of diagnosing rejection of a kidney allograft using genomic or proteomic expression profiling |
| FR2971713B1 (fr) | 2011-02-18 | 2019-03-29 | Laboratoire De La Mer | Solution ionique aqueuse contenant de l'eau de mer et au moins un compose originellement non miscible a l'eau de mer. |
| WO2015129800A1 (ja) * | 2014-02-26 | 2015-09-03 | セオリアファーマ株式会社 | ジオクチルソジウムスルホサクシネート耳鼻科用液剤 |
| CA2984589A1 (en) | 2015-05-01 | 2016-11-10 | The University Of British Columbia | Biomarkers for the detection of acute rejection in heart transplantation |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4581226A (en) * | 1983-04-07 | 1986-04-08 | Dillon Richard S | Method of treating sensitive animal tissue with a specially processed seawater solution |
| JP2912421B2 (ja) * | 1990-05-10 | 1999-06-28 | 千寿製薬株式会社 | 水性液剤 |
| US5296472A (en) * | 1991-12-05 | 1994-03-22 | Vyrex Corporation | Methods for delipidation of skin and cerumen removal |
| FR2688133A1 (fr) * | 1992-03-06 | 1993-09-10 | Plantes Tropicales Lab | Composition d'hygiene a base d'eau de mer. |
| FR2735021B1 (fr) * | 1995-06-08 | 1998-02-27 | Maugendre Renee Jane | Procede de preparation d'eau de mer pour la desagregation du cerumen |
| FR2735980B1 (fr) * | 1995-06-30 | 1997-09-12 | Sun Trading Ltd | Nouvelles preparations pour l'otologie et leur procede de preparation |
-
1998
- 1998-06-29 FR FR9808249A patent/FR2780284B1/fr not_active Expired - Fee Related
-
1999
- 1999-06-29 AU AU43765/99A patent/AU4376599A/en not_active Abandoned
- 1999-06-29 US US09/743,010 patent/US6709680B1/en not_active Expired - Fee Related
- 1999-06-29 ES ES99926567T patent/ES2172332T3/es not_active Expired - Lifetime
- 1999-06-29 JP JP2000556793A patent/JP2002519330A/ja active Pending
- 1999-06-29 PT PT99926567T patent/PT1091746E/pt unknown
- 1999-06-29 CA CA2335913A patent/CA2335913C/fr not_active Expired - Fee Related
- 1999-06-29 DK DK99926567T patent/DK1091746T3/da active
- 1999-06-29 AT AT99926567T patent/ATE212553T1/de not_active IP Right Cessation
- 1999-06-29 EP EP99926567A patent/EP1091746B1/fr not_active Expired - Lifetime
- 1999-06-29 WO PCT/FR1999/001564 patent/WO2000000208A1/fr not_active Ceased
- 1999-06-29 DE DE69900852T patent/DE69900852T2/de not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| DE69900852T2 (de) | 2002-09-12 |
| FR2780284B1 (fr) | 2001-10-05 |
| ES2172332T3 (es) | 2002-09-16 |
| DK1091746T3 (da) | 2002-05-21 |
| US6709680B1 (en) | 2004-03-23 |
| WO2000000208A1 (fr) | 2000-01-06 |
| JP2002519330A (ja) | 2002-07-02 |
| EP1091746B1 (fr) | 2002-01-30 |
| AU4376599A (en) | 2000-01-17 |
| FR2780284A1 (fr) | 1999-12-31 |
| PT1091746E (pt) | 2002-07-31 |
| ATE212553T1 (de) | 2002-02-15 |
| CA2335913A1 (fr) | 2000-01-06 |
| EP1091746A1 (fr) | 2001-04-18 |
| DE69900852D1 (de) | 2002-03-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1196185B1 (fr) | Nouvelle utilisation de solutions salines hypoosmotiques et medicament a base de ces solutions | |
| CA2335913C (fr) | Utilisation de solutions salines isoosmotiques, leur procede de preparation et medicaments cerumenolytiques a base de ces solutions | |
| CA2154730C (fr) | Nouvelles compositions a base d'un melange synergetique entre au moins un ligand specifique des rxrs et au moins un ligand specifique de rar-.alpha., et leurs utilisations | |
| US4987127A (en) | Method of treating a virus outbreak | |
| JP3962666B2 (ja) | 皮膚外用剤 | |
| WO1998025586A1 (fr) | Formulation a usage dermatologique | |
| JP2008019180A (ja) | リパーゼ阻害剤、角栓形成抑制剤、毛穴目立ち抑制剤およびニキビ抑制剤 | |
| WO2008145926A2 (fr) | Procede de traitement de la propolis | |
| RU2076699C1 (ru) | Антимастопатийная мазь "мамматон" | |
| Kuokkanen et al. | Hyperkeratosis lenticularis perstans (Flegel´ s disease) | |
| Flemström et al. | The disappearance of acetic acid and acetate from the cat's stomach and its influence on the permeability for hydrochloric acid | |
| EP1051979B1 (fr) | Utilisation de lipides peroxydés pour prévenir et/ou traiter les effets irritants d'un principe actif | |
| Mutta | A Review on Emulgel | |
| JPH0333684B2 (enExample) | ||
| WO2019233158A1 (zh) | 中药凝胶组合物及其制备方法和用途 | |
| FR2622800A1 (fr) | Procede de preparation d'un produit de lutte contre des affections virales en particulier des affections virales cutaneo-muqueuses,compositions pharmaceutiques et medicaments obtenus a partir de ce procede | |
| WO2002067891A1 (fr) | Composition cosmetique a base de nicotine libre et utilisations | |
| RU2648441C2 (ru) | Средство для местной анестезии (варианты) | |
| FR2834206A1 (fr) | Composition cosmetique contenant une huile extraite de graines de murumuru, son utilisation cosmetique, et composition pharmaceutique contenant une huile extraite de graines de murumuru | |
| JP2007022915A (ja) | 外用塗布薬 | |
| BE899917Q (fr) | Compositions pharmaceutiques de reglisse deglycyrrhizinee. | |
| WO2005060948A1 (fr) | Utilisation du fepradinol pour la preparation d’une composition pharmaceutique pour le traitement de la rosacee | |
| JPH0227964B2 (enExample) | ||
| WO2024134110A1 (fr) | Insaponifiable d'avocat pour son utilisation dans le traitement de pathologies induites par une levure malassezia | |
| WO2005034972A2 (fr) | Utilisation de compositions pharmaceutiques contenant de l'huile d’onagre pour traiter la xerostomie |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKLA | Lapsed |
Effective date: 20170629 |